Enspryng™ (satralizumab-mwge) – New orphan drug approval
August 17, 2020 - The FDA announced the approval of Genentech’s Enspryng (satralizumab-mwge), for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
Download PDF
